
Noble E. Jarrell
Examiner (ID: 14167, Phone: (571)272-9077 , Office: P/1625 )
| Most Active Art Unit | 1699 |
| Art Unit(s) | 1625, 1699, 1622, 1624, 1609 |
| Total Applications | 1419 |
| Issued Applications | 950 |
| Pending Applications | 180 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19402269
[patent_doc_number] => 20240285780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => PEPTIDE EXHIBITING BOTULINUM TOXIN-LIKE ACTIVITY, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/009388
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009388
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009388 | PEPTIDE EXHIBITING BOTULINUM TOXIN-LIKE ACTIVITY, AND USE THEREOF | Jun 10, 2021 | Pending |
Array
(
[id] => 18597138
[patent_doc_number] => 20230271930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => PROCESS FOR ISOLATION AND PURIFICATION OF THCA FROM CANNABIS
[patent_app_type] => utility
[patent_app_number] => 18/009029
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009029
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009029 | PROCESS FOR ISOLATION AND PURIFICATION OF THCA FROM CANNABIS | Jun 7, 2021 | Pending |
Array
(
[id] => 18530258
[patent_doc_number] => 20230235328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 18/007830
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007830
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/007830 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | Jun 6, 2021 | Pending |
Array
(
[id] => 17126104
[patent_doc_number] => 20210300872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => SECOND GENERATION GRP94-SELECTIVE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/341047
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/341047 | Second generation GRP94-selective inhibitors | Jun 6, 2021 | Issued |
Array
(
[id] => 19681546
[patent_doc_number] => 20250000091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/000777
[patent_app_country] => US
[patent_app_date] => 2021-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36925
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000777
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000777 | GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF | Jun 4, 2021 | Pending |
Array
(
[id] => 18468741
[patent_doc_number] => 20230203023
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => SALT AND CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/927502
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927502
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927502 | SALT AND CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF | May 25, 2021 | Pending |
Array
(
[id] => 19904084
[patent_doc_number] => 12281080
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-22
[patent_title] => Quinoline-based compounds and methods of inhibiting CDK8/19
[patent_app_type] => utility
[patent_app_number] => 17/330279
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 33
[patent_no_of_words] => 16561
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330279
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330279 | Quinoline-based compounds and methods of inhibiting CDK8/19 | May 24, 2021 | Issued |
Array
(
[id] => 18435921
[patent_doc_number] => 20230183215
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => Notch Inhibitors and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/925916
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 92326
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -79
[patent_words_short_claim] => 612
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925916
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925916 | Notch Inhibitors and Uses Thereof | May 20, 2021 | Pending |
Array
(
[id] => 20453020
[patent_doc_number] => 12516070
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Fused ring derivatives and use thereof in pharmacy
[patent_app_type] => utility
[patent_app_number] => 17/926285
[patent_app_country] => US
[patent_app_date] => 2021-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 21296
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926285 | Fused ring derivatives and use thereof in pharmacy | May 17, 2021 | Issued |
Array
(
[id] => 18877404
[patent_doc_number] => 20240000773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/925798
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12028
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925798 | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof | May 16, 2021 | Issued |
Array
(
[id] => 18420060
[patent_doc_number] => 20230174521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/924780
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924780
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/924780 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | May 12, 2021 | Pending |
Array
(
[id] => 17988922
[patent_doc_number] => 20220354959
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/318723
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 96071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318723
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/318723 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | May 11, 2021 | Abandoned |
Array
(
[id] => 18511343
[patent_doc_number] => 20230227485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => METAL IRIDIUM COMPLEX AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/928908
[patent_app_country] => US
[patent_app_date] => 2021-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9691
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 280
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928908
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/928908 | METAL IRIDIUM COMPLEX AND USE THEREOF | May 8, 2021 | Pending |
Array
(
[id] => 20057279
[patent_doc_number] => 20250195501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-19
[patent_title] => CELL ENTRY-MODULATING AGENTS AND USES THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/998099
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998099
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998099 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | May 6, 2021 | Pending |
Array
(
[id] => 18449651
[patent_doc_number] => 20230190927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/923421
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923421
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923421 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | May 3, 2021 | Pending |
Array
(
[id] => 18420023
[patent_doc_number] => 20230174484
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => ANTAGONISTS OF GPR39 PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/997533
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -103
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997533
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997533 | ANTAGONISTS OF GPR39 PROTEIN | Apr 29, 2021 | Pending |
Array
(
[id] => 20401188
[patent_doc_number] => 12491147
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Personal care compositions comprising a metal piroctone complex
[patent_app_type] => utility
[patent_app_number] => 17/923733
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2095
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923733
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923733 | Personal care compositions comprising a metal piroctone complex | Apr 28, 2021 | Issued |
Array
(
[id] => 20271912
[patent_doc_number] => 12441681
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Synthesis of sulfonamide intermediates
[patent_app_type] => utility
[patent_app_number] => 17/923015
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4385
[patent_no_of_claims] => 80
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923015
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923015 | Synthesis of sulfonamide intermediates | Apr 27, 2021 | Issued |
Array
(
[id] => 19777385
[patent_doc_number] => 12226405
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use
[patent_app_type] => utility
[patent_app_number] => 17/241981
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 17
[patent_no_of_words] => 61767
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241981
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/241981 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | Apr 26, 2021 | Issued |
Array
(
[id] => 18468773
[patent_doc_number] => 20230203055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE
[patent_app_type] => utility
[patent_app_number] => 17/997328
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997328 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | Apr 26, 2021 | Abandoned |